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ABSTRACT
Subependymal giant cell astrocytomas (SEGAs) are rare, low-grade 
glioneuronal brain tumors that occur almost exclusively in patients with tuberous 
sclerosis complex (TSC). Though histologically benign, SEGAs can lead to serious 
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neurological complications, including hydrocephalus, intractable seizures and death. 
Previous studies in a limited number of SEGAs have provided evidence for a biallelic 
two-hit inactivation of either TSC1 or TSC2, resulting in constitutive activation of 
the mechanistic target of rapamycin complex 1 pathway. The activating BRAF V600E 
mutation is a common genetic alteration in low grade gliomas and glioneuronal 
tumors, and has been reported in SEGAs as well. In the present study, we assessed 
the prevalence of the BRAF V600E mutation in a large cohort of TSC related SEGAs 
(n=58 patients including 56 with clinical TSC) and found no evidence of either 
BRAF V600E or other mutations in BRAF. To confirm that these SEGAs fit the classic 
model of two hit TSC1 or TSC2 inactivation, we also performed massively parallel 
sequencing of these loci. Nineteen (19) of 34 (56%) samples had mutations in 
TSC2, 10 (29%) had mutations in TSC1, while 5 (15%) had no mutation identified 
in TSC1/TSC2. The majority of these samples had loss of heterozygosity in the 
same gene in which the mutation was identified. These results significantly extend 
previous studies, and in agreement with the Knudson two hit mechanism indicate 
that biallelic alterations in TSC2 and less commonly, TSC1 are consistently seen in 
SEGAs.
INTRODUCTION
Subependymal giant cell astrocytomas (SEGAs) 
are rare, low-grade brain tumors that generally develop 
during the first two decades of life in 10-20% of patients 
with tuberous sclerosis complex (TSC) [1–3]. TSC is an 
autosomal dominant neurocutaneous disorder caused by 
mutations in either TSC1 encoding hamartin, or TSC2 
encoding tuberin. Together these two proteins form 
the TSC protein complex that regulates mechanistic 
target of rapamycin complex 1 (mTORC1) [4–6]. In 
the central nervous system, TSC is characterized by the 
development of SEGAs, subependymal nodules (SEN), 
cortical tubers and cortical migration tracts [7]. SEGAs 
represent 1%-2% of all pediatric brain tumors and 
usually arise near the foramen of Monro [8–10]. They 
are a potential cause of major morbidity and mortality 
in TSC [11]. Extended growth of the tumor can cause 
obstruction of cerebrospinal fluid tract resulting in 
hydrocephalus and increased intracranial pressure with 
subsequent death if neglected. SEGAs are treated with 
either surgical resection or mTORC1 inhibitors including 
everolimus.
Histopathologically, SEGAs consist of spindle 
cells, gemistocytic-like cells and giant cells. According 
to the present world health organization (WHO) 
classification of brain tumors, SEGAs belong to the 
group of astrocytic neoplasms, even though they have 
both glial and neuronal expression patterns [12, 13]. 
SEGAs likely develop from SEN, but the molecular 
mechanisms underlying their progressive growth, in 
contrast to SEN, are unknown so far [14, 15]. There is 
evidence of second-hit inactivation of TSC1 or TSC2 
in SEGAs, suggesting that one contributor to SEGA 
development is the complete loss of a functional 
tuberin-hamartin complex and the subsequent mTORC1 
activation [16–18]. However, it is likely that second-hit 
mutations in TSC1 and TSC2 also contribute to SEN 
formation, suggesting that additional genetic events may 
contribute to the progressive growth of SEGAs.
BRAF is a kinase that activates the mitogen-
activated protein kinase/extracellular signal-regulated 
kinase (MAPK/ERK) pathway which regulates cell 
proliferation, survival and cell-cycle arrest [19]. The 
BRAF c.1799T>A (p.V600E) mutation (BRAFV600E) 
results in constitutive activation of MAPK/ERK 
signaling and is well known in both pediatric 
and adult low-grade gliomas, including pilocytic 
astrocytoma (PA), pleomorphic xanthoastrocytoma 
(PXA), ganglioglioma (GG), desmoplastic infantile 
gangliogliomas (DIG), and dysembyoplastic 
neuroepithelial tumor (DNET) [20–26]. Although the 
prevalence of BRAF mutations in low grade gliomas 
is relatively low [22], BRAFV600E mutations have been 
consistently reported as genetic driver in gangliogliomas 
(18-56%), and have been associated with mTORC1 
activation [20, 25]. 
Both protein kinase B (AKT) and MAPK/ERK 
pathways have been reported to be activated in SEGAs 
[27–31]. However, the genetic basis for MAPK/
ERK and AKT activation in SEGAs is unknown. The 
BRAFV600E mutation was reported in a small set (6 of 14 
cases) of SEGAs [23] suggesting that it could explain 
MAPK/ERK and AKT activation in SEGAs. However, 
subsequent studies have produced contradictory 
results, failing to confirm the presence of the BRAFV600E 
mutation in SEGAs [18, 21, 23, 26, 32].
In the present study, we examined the possibility that 
BRAF mutations occur in SEGA using a large international 
cohort of fifty-eight SEGAs from both pediatric and adult 
TSC patients.
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RESULTS
Samples and clinical features
Fifty-eight SEGAs and one SEN from 58 patients 
were analyzed (62% male, 36% female; Table 1). Fifty-six 
patients had a definite clinical diagnosis of TSC, whereas 
two patients did not show other signs of TSC apart from 
the tumor. TSC1/TSC2 mutation analysis was performed 
as part of routine clinical care on blood or tumor DNA 
for 19 subjects, such that 7 had TSC1 and 12 had TSC2 
mutations. For 34 samples we performed TSC1/TSC2 
mutation analysis using massively parallel sequencing 
(MPS); for the remaining 5 samples there was insufficient 
DNA for this analysis.
Ages ranged from 1 to 53 years at the time of 
surgery. The large majority of patients had a lesion located 
in the lateral ventricle near the foramen of Monro and 
five patients had bilateral tumors. Histological diagnosis 
was confirmed following the current WHO classification 
guidelines by two independent neuropathologists [33]. 
All cases had classical histological features of SEGA, 
showing mainly giant cells with eosinophilic cytoplasm 
(Figure 1A). Smaller gemistocytic cells, fibrillary 
astrocytes and a variable number of multinucleated cells 
were also noted in all cases. Calcifications were observed 
in 13/44 FFPE cases (30%). As previously reported [13, 
34–36], immunohistochemical analysis revealed variable 
expression of glial and neuronal markers (Figures 1B-1C). 
We also observed prominent presence of microglial cells 
intratumoral T-lymphocytes (Figures 1D-1E) and evidence 
of activation of mTORC1 pathway with phospho-S6 
ribosomal protein immunoreactivity (Figure 1F). The 
differential diagnosis of SEGA takes into account other 
tumors arising in the region of the basal ganglia and in 
the lateral and third ventricles (diffuse astrocytoma, 
ependymoma, central neurocytoma, choroid plexus 
papilloma). SEGA outside the setting of TSC are rare [37, 
38], as well as SEGA within cortical tubers [39]. In our 
cohort, nearly all patients (n=56) had other central nervous 
system TSC-associated lesions (SEN and cortical tubers) 
associated with refractory epilepsy, making the diagnosis 
reasonably certain before resection.
BRAF mutational analysis
Sanger sequencing analysis for the BRAFV600E 
mutation in all 58 SEGA samples tested and the SEN was 
negative (Figure 2). Furthermore, no other variants were 
found in exon 15 of BRAF in any sample. We also performed 
RT-PCR to screen for five different types of gene fusions 
between KIAA1549 and BRAF on 6 SEGAs from which 
RNA was available (Table 2; data not shown). There was 
no evidence for the presence of KIAA1549-BRAF fusions 
in the six SEGA cases analyzed. BRAF mutational analysis 
was also performed by MPS for all SEGA samples for 
which there was sufficient DNA to permit this method of 
analysis, n=31 (Table 3B). None of the samples showed 
the BRAFV600E mutation, even at an allele frequency of 
5-10%. Five intronic variants were identified, all known 
single nucleotide polymorphisms (SNPs; data not shown). 
Two coding variants in exon 1 were identified, c.82G>T 
(p.G28C) at allele frequency 100% in one sample, and 
c.31G>Ap (p.G11S) at allele frequency 56% in a second 
sample (Table 3B). These are not known germline variants 
(per Exac). The p.G11S variant has been reported in a single 
hepatocellular carcinoma, while the p.G28C variant has not 
been seen previously in cancer (per cBio). Furthermore, 
these two variants  showed no evidence of pathogenicity 
based on three different in silico prediction tools.
Table 1: Summary of clinicopathological features in TSC patients with subependymal giant cell astrocytoma
Parameter Number %
Age
  ≤18
 >18
37
21
64
36
Sex
 Male
 Female
36
22
62
37
Tumor location
 Lateral ventricle
 Foramen of Monro
 Third ventricle
49
5
4
84
9
7
TSC-lesions
 SEN/Tubers 56 96
Tuberous Sclerosis Complex
 Definite
 Possible
56
2
97
3
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TSC1/TSC2 mutational analysis
TSC1/TSC2 mutational analysis was performed by 
MPS for 34 SEGA samples (Table 3A, Figures 3 and 4). In 
19 (56%) samples TSC2 mutation was identified, 10 (29%) 
had mutations in TSC1, and 5 (15%) had no mutation 
identified (NMI) in either TSC1 or TSC2. Of the 5 NMI 
samples 3 showed copy neutral loss of heterozygosity 
(CN-LOH) for TSC2 and another sample had a possible 
TSC1 mutation. Nine of 10 (89%) samples with a TSC1 
mutation also showed evidence of CN-LOH for TSC1, 14 
of 19 (74%) samples with a TSC2 mutation also showed 
evidence of CN-LOH for TSC2, while in 1 sample two 
small TSC2 mutations were identified.
DISCUSSION
SEGAs are low-grade brain tumors associated 
with TSC and represent 1%-2% of all pediatric brain 
Figure 1: Subependymal giant cell astrocytomas (SEGAs). (A) Hematoxylin and eosin staining of a SEGA tumor presenting 
classical histological features, with giant cells (large cells with abundant eosinophilic cytoplasm and nuclei with prominent nucleoli; high 
magnification in insert) in a mixed glial background and blood vessels. (B) GFAP showing areas of diffuse immunoreactivity. (C) Variable 
expression of neuronal markers, including MAP2 is observed within the tumor (arrow shows MAP2 expression in a giant cell). (D) HLA-
DR shows prominent presence of microglial cells. (E) CD3 staining shows intratumoral T lymphocytes (arrows). (F) pS6 shows several 
positive tumor cells. Scale bars: 80 μm.
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Table 2: Primer sequences for detection of KIAA1549:BRAF fusion genes
Gene Exon variant (KIAA1549:BRAF) Forward Primer (5’->3’) Reverse primer (5’->3’)
KIAA1549-BRAF fusion Ex16:Ex9 CTACAGCCCAGCCCAGAC GTGAGCCAGGTAATGAGGCAG
KIAA1549-BRAF fusion Ex15:Ex9 CCACAACTCAGCCTACATCGG GTGAGCCAGGTAATGAGGCAG
KIAA1549-BRAF fusion Ex16:Ex11 AGACGGCCAACAATCCCTGC GTCCCACTGTAATCTGCCC
KIAA1549-BRAF fusion Ex18:Ex10 GAGGGATCTACTCGGAGGAG GTGAGCCAGGTAATGAGGCAG
KIAA1549-BRAF fusion Ex19:Ex9 GAAGCGGGGCGAAGAGAG GTGAGCCAGGTAATGAGGCAG
PBGD - CTGGTAACGGCAATGCGGCT GCAGATGGCTCCGATGGTGA
B2M - AGCATTCAGACTTGTTTCAG GATGCTGCTTAGATGTCTCG
Figure 2: Direct sequencing of exon 15 of BRAF for detection of the V600E mutation. (A) Schematic overview showing the 
forward and reverse sequence of BRAF exon 15 at codon 598 through codon 602 for both wild-type and the c.1799T>A (p.V600E) mutation. 
(B) Positive control. Pilocytic astrocytoma with the BRAFV600E mutation shows c.1799T>A in the forward sequence (left) and reverse 
sequence (right), resulting in the p.V600E amino acid substitution (arrow). (C) SEGA showing the wild-type GTG forward sequence (left) 
and CAC reverse sequence (right). (D) SEN with the V600 codon showing the wild-type GTG forward sequence (left) and CAC reverse 
sequence (right). Arrows indicate codon 600 of BRAF.
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Table 3A: Summary of results for TSC1/TSC2 mutational analysis in 34 SEGA samples by MPS. NMI = No Mutation 
Identified, MAF = mutant allele frequency, CN-LOH = Copy neutral loss of heterozygosity, point = point mutation 
or small insertion or deletion
Case 
(#) Gene Nucleotide change
MAF 
(%)
Mutation 
type Protein change
CN-
LOH Summary
1 NMI
2 NMI TSC1 c.1-7G>A 50 Possible initiator No Possible TSC1 mutation, no CN-LOH
3 TSC1 chr9:135700060-135799506del 78
Genomic 
deletion
deletion of 
exons 6-23 Yes large del+ CN-LOH
4 TSC1 c.1498C>T 71 Nonsense p.R500* Yes point+CN-LOH
5 TSC1 c.641_644dupAGAC 93 Insertion p.F216Dfs*3 Yes point+CN-LOH
6 TSC1 c.2074C>T 39 Nonsense p.R692* Yes point+CN-LOH
7 TSC1 c.1525C>T 12 Nonsense p.R509* No Point-no LOH
8 TSC1 c.2699dupA 65 Insertion p.Q901Efs*3 Yes point+CN-LOH
9 TSC1 c.1802dupC 79 Insertion p.P602Sfs*4 Yes point+CN-LOH
10 TSC1 c.935dupA 29 Nonsense p.Y312* Yes point+CN-LOH
11 TSC1 c.1525C>T 76 Nonsense p.R509* Yes point+CN-LOH
12 TSC1 c.2695C>T 70 Nonsense p.Q899* Yes point+CN-LOH
13 TSC2 c.4375C>T 50 Nonsense p.R1459* No point no LOH (sporadic SEGA; no other signs of TSC)
14 TSC2 c.3412C>T 68 Nonsense p.R1138* Yes point+CN-LOH
15 TSC2 c.2353C>T 12 Nonsense p.Q785* Yes point+CN-LOH
16 TSC2 c.2221-1G>C 55 Splice p.L741_splice Yes point+CN-LOH
17 TSC2 c.790_791delCT 30 Deletion p.L264Wfs*73 No Point, no LOH
18 TSC2
c.903_922delGGCT
CTCTGGGGAGCC
CACC
34 Deletion p.W304Ffs*27 Yes point+CN-LOH
19 TSC2
c.5227_5244delCG
GCTCCGCCACAT
CAAG
72 In-frame deletion
p.R1743_
K1748del Yes point+CN-LOH
20 TSC2 c.1832G>A 65 Missense p.R611Q Yes point+CN-LOH
21 TSC2 c.3526_3527insT 38 Insertion p.P1176fs Yes point+CN-LOH
22 TSC2 c.1513C>T 47 Nonsense p.R505* Yes point+CN-LOH
23 TSC2 c.3171_3172insA 17 Insertion p.T1059Nfs*109 No point -no LOH
24 TSC2 c.268C>T 75 Nonsense p.Q90* Yes point+CN-LOH
25 TSC2 c.2251C>T 63 Nonsense p.R751* Yes point+CN-LOH
26 TSC2
c.5227_5244delCG
GCTCCGCCACAT
CAAG
80 In-frame deletion
p.R1743_
K1748del Yes
point+CN-LOH (sporadic SEGA; no 
other signs of TSC)
27 TSC2 c.5168C>A 34 Nonsense p.S1723* Yes point+CN-LOH
28 TSC2 c.3599G>C 57 Missense p.R1200P Yes point+CN-LOH
(Continued)
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tumors [1, 10]. Due to the scarcity of resected SEGAs, 
studies to investigate the genetic profile of this tumor 
type have been restricted to a small number of samples/
cases. More specifically, investigation of the presence 
of a BRAFV600E mutation in SEGAs has been limited to 
four individual studies with controversial results [18, 23, 
26, 32].
In the present study, we analyzed the largest SEGA 
cohort to date, consisting of fifty-eight SEGAs. Amongst 
the cohort the vast majority of cases (97%) were clinically 
diagnosed as definite TSC meeting the required criteria 
[40, 41]. We did not detect the cancer-actionable BRAFV600E 
mutation by direct sequencing or in the MPS analysis 
in any of the samples tested. Furthermore, there was no 
evidence for the presence of KIAA1549-BRAF fusions in 
the 6 SEGAs that were analyzed. However, no significant 
conclusions on BRAF fusion mutations in SEGAs could 
be drawn based on this small sample size (N=6). In the 
studies that have reported SEGA cases with BRAFV600E 
mutations, only two were diagnosed with definite TSC, 
while the remaining BRAFV600E positive samples were 
either TSC negative or defined as possible TSC [23, 26]. 
Altogether, these results suggest that SEGAs derived from 
patients with TSC, are negative for the BRAFV600E mutation 
[18, 21, 23, 26, 32].
Additionally, our results indicate that TSC1/TSC2 
alterations, including CN-LOH, are nearly universally 
present in SEGAs, consistent with TSC1/TSC2 
molecular findings seen in other TSC-related 
tumors e.g. renal angiomyolipomas (AMLs) and 
lymphangioleiomyomatosis (LAM) [42]. TSC2 LOH has 
also been reported in sporadic renal and hepatic AMLs 
as well as sporadic perivascular epithelioid cell tumors 
[42,43]. Conversely, TSC1 mutation and LOH is rare in 
angiomyolipoma and perivascular epithelioid cell tumors 
[42-45].  In contrast TSC1 mutations and LOH were 
relatively common in this series, seen in 10 of 34 (29%) 
and 9 of 34 (26%), respectively.  Regarding the 5 SEGA 
cases in which no definite small mutation was identified, 
there are several possible causes.  First the DNA quality 
of many SEGA samples was poor, limiting the sensitivity 
of the MPS analysis.  In particular large genomic deletions 
may have been missed in this analysis, and are relatively 
common in TSC2 [42].
Consequently, the mechanism of MAPK/ERK and 
AKT pathway activation in SEGAs [27–31] is uncertain, 
and further investigation is required. 
Case 
(#) Gene Nucleotide change
MAF 
(%)
Mutation 
type Protein change
CN-
LOH Summary
29 TSC2 c.1372C>T 32 Nonsense p.R458* Yes point+CN-LOH
30 TSC2 c.3814+1G>C 47 Splice p.V1272_splice No 2 points
c.1831C>T 15 Missense p.R611W
31 TSC2 c.412G>T 51 Nonsense p.E138* No point no LOH
32 TSC2 Yes TSC2 CN-LOH,no point
33 TSC2 Yes TSC2 CN-LOH,no point
34 TSC2 Yes TSC2 CN-LOH,no point
Table 3B: Summary of results for BRAF mutational analysis by MPS in 31 SEGA samples
Case 
(#) Gene Nucleotide change
MAF 
(%) Mutation type Protein change Summary
25 BRAF c.82G>T 100 Missense p.G28C Novel per cBio,not seen in ExAC
8 BRAF c.31G>A 56 Missense p.G11S
Seen once in an 
hepatobiliary cancer 
(cBio), not seen in 
ExAC
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Figure 3: Map of TSC1 and TSC2 mutations identified in 10 and 19 SEGA tumors, respectively. Novel variants (n = 9) 
are in blue font whereas variants previously reported (n = 16) are in black font. Circle colors present different mutation types, as indicated. 
(A) Map of TSC1 mutations. One TSC1 mutation (p.R509*) was seen in two different tumor samples; a large genomic deletion (deletion of 
exons 6-23) and a possible TSC1 mutation (c.1-7G>A) are not shown. (B) map of TSC2 mutations. Two TSC2 mutations differ by a single 
nucleotide position in the same amino acid (p.R611Q/ p.R611W), and hence their circles overlap; one TSC2 mutation (p.R1743_K1748del) 
was seen in two different tumor samples.
Figure 4: Pie charts demonstrating the TSC1/TSC2 variant types and mutant allele frequencies in the SEGA tumors 
analyzed. (A) Percentage of subjects with TSC1/TSC2 mutations identified vs. NMI. (B) Different mutation types in the SEGA cohort 
studied.
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MATERIALS AND METHODS
SEGA tumor specimens
SEGA specimens were obtained from the 
following sites: the Academic Medical Center of 
Amsterdam, the University Medical Center Utrecht, 
University Medical Center Groningen, University 
Hospital Erlangen, University Hospital Münster, 
Medical University of Vienna, Children’s Memorial 
Health Institute in Warsaw, Meyer Children's Hospital 
in Florence, Hacettepe University in Ankara, and the 
University Hospital de Santa Maria (CHLN) University 
Hospital de Santa Maria (CHLN) in Lisbon. Fifty-eight 
SEGAs and one SEN were available from 58 patients 
of which 56 met standard diagnostic criteria for TSC 
(Table 1) [40, 41]. Specimens were obtained and used 
in accordance with the Declaration of Helsinki and this 
study was approved by the Medical Ethics Committee 
of each institution.
Histopathological evaluation
Tissue was fixed in 10% buffered formalin and 
embedded in paraffin. Paraffin-embedded tissue was 
sectioned  at  6  μm,  mounted  on  organosilane-coated 
slides (Sigma, St. Louis, MO, USA) and stained 
with hematoxylin-eosin (HE) for the morphological 
evaluation. Histological diagnosis was performed 
according to the 2016 WHO classification of the central 
nervous system [33]. Sections of the most representative 
paraffin-embedded specimen of each case were used for 
additional immunocytochemical staining, as previously 
reported [34, 35]. The following antibodies have been 
used: glial fibrillary acidic protein (GFAP; polyclonal 
rabbit, DAKO, Glostrup, Denmark; 1:4000; monoclonal 
mouse; DAKO; 1:50), microtubule-associated protein 
(MAP2; mouse clone HM2; Sigma 1:100), anti-human 
leukocyte antigen (HLA)-DP, DQ, DR (mouse clone 
CR3/43; DAKO; 1:100), CD3 (mouse monoclonal, 
clone F7.2.38; DAKO; 1:200; T-lymphocytes), 
phospho-S6 ribosomal protein (Ser235/236; pS6, rabbit 
polyclonal, Cell Signaling Technology, Beverly, MA, 
USA; 1:50) and Ki67 (mouse clone MIB-1, DAKO, 
Glostrup, Denmark. 1:20) were used in the routine 
immunocytochemical analysis of tumor specimens to 
document the presence of a heterogeneous population of 
cells and the activation of the mTORC1 pathway. After 
washing in PBS, sections were stained with a polymer 
based peroxidase immunocytochemistry detection 
kit (BrightVision Peroxidase system, ImmunoVision, 
Brisbane, CA, USA). Signal was detected using the 
chromogen 3-amino-9-ethylcarbazole (AEC, Sigma-
Aldrich, St. Louis, MO, USA).
DNA extraction and BRAFV600E mutation analysis
DNA was extracted from both FFPE (n=44) and 
frozen (n=14) SEGA tumor samples. Since SEGA often 
display intratumoral hemorrhages, areas of representative 
tumor (identified on hematoxylin & eosin stained 
sections) were selected for cases in which hemorrhages, 
were observed within the FFPE SEGA tissue samples 
(n=44).  Tumor  DNA  was  extracted  from  10-μm-thick 
paraffin sections using BiOstic FFPE Tissue DNA 
Isolation kit (MO BIO) according to the manufacturer’s 
instructions. From frozen tissue samples (N=14) DNA 
was recovered from the organic phase following QIAzol 
(Qiagen) extraction of RNA and was further purified using 
QIAamp DNA mini Kit (Qiagen). PCR amplification 
for the entire extent of exon 15 of BRAF including 
codon 600 was performed as previously described 
using primers TCATAATGCTTGCTCTGATAGGA and 
GGCCAAAAATTTAATCAGTGGA [26]. Purified PCR 
products were sequenced by the Sanger method using the 
Big Dye Terminator Cycle Sequencing Kit (PerkinElmer 
Biosystems, Foster City, CA, USA).
KIAA1549–BRAF gene fusion
Six SEGA tissue samples were tested for KIAA1549-
BRAF fusions in a diagnostic setting. Total RNA was 
extracted from frozen tissue samples using miRNeasy mini 
kit (Qiagen) according to the manufacturer’s instructions. 
One microgram of total RNA was reverse-transcribed into 
cDNA, followed by PCR using primer sets corresponding 
to different KIAA1549-BRAF fusion genes and the PBGD 
and B2M reference genes (Table 2). PCR products were 
analyzed on a 2% agarose gel. Pilocytic astrocytoma tissue 
containing the KIAA1549-BRAF fusions was used as a 
positive control. Additionally, tonsil tissue known to lack 
the KIAA1549-BRAF fusion genes was used as a negative 
control.
TSC1/TSC2 mutation and LOH analysis of 
SEGAs
In 3 cases (fresh frozen samples), targeted MPS 
was performed using a HaloPlex custom capture array 
as described previously [46]. In the other 31 cases (24 
FFPE and 7 fresh frozen samples), targeted MPS was 
performed using a customized gene bait set (Agilent 
platform) designed in the Kwiatkowski lab that covers the 
entire TSC1 and TSC2 genes including 10 kb upstream 
and downstream and all coding exons and introns. This 
bait set also covered all coding exons and adjacent introns 
of BRAF. MPS was performed according to the following 
methods. Briefly, DNA was subjected to fragmentation 
using Covaris sonication to an average size of 250bp. The 
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fragmented DNA was purified using Agencourt AMPure 
XP beads and ligated to the dual indexed adaptors for 
Illumina sequencing. A MiSeq run was performed to 
quantify each library. Libraries were then pooled in equal 
mass and captured using the custom baitset using Agilent 
SureSelect hybrid capture kit. The captured libraries were 
then sequenced on the either the HiSeq2500 or the HiSeq 
3000 instrument.
The sequencing output was de-convoluted into 
individual sample reads and sorted using Picard tools [47]. 
Reads were aligned to the reference sequence hg19 from 
the Human Genome Reference Consortium using bwa [42, 
48–50], and duplicate reads were identified and marked 
using the Picard tools. The alignments were further refined 
using the GATK tool for localized realignment around 
indel sites and recalibration of the quality scores was 
also performed using GATK tools [42, 49, 51]. Mutation 
analysis for single nucleotide variants (SNV) was 
performed using MuTect v1.1.4 and annotated by Variant 
Effect Predictor (VEP) [52, 53]. Insertions and deletions 
were called using Indel Locator and SomaticIndelDetector 
tool [42, 54]. MuTect was run in paired mode using a 
CEPH sample as a normal since normal DNA samples 
were not available, and a germline variant filter was then 
applied. Variants were filtered against the 6,500 exome 
release of the Exome Sequencing Project (ESP) database 
ExAC (exclude variants seen in more than 3 normal 
subjects; http://exac.broadinstitute.org), 1000G and 
GnomAD [55, 56]. Variants represented at >1% in either 
the African-American or European-American subsets of 
these reference databases and not in COSMIC > 2x were 
considered to be germline. Variants found in BRAF were 
analysed using cBio (http://www.cbioportal.org) and were 
further assessed for functionality using 3 different in silico 
prediction tools: PROVEAN (http://provean.jcvi.org), 
SIFT (http://sift.jcvi.org) and MutationAccessor (http://
mutationassessor.org) [57–61].
A second approach was used in parallel to analyze 
the sequence data, with capture of read calls at all 
positions using SAMtools Pileup, followed by custom 
processing in Python and Matlab to determine base call 
frequency at each position in each read orientation. These 
data were then filtered to eliminate variant calls observed 
in only a single read orientation, or seen in multiple 
samples to exclude artifacts derived from the sequencing 
process. All variants observed at a frequency of >1% were 
directly reviewed using the Integrative Genomics Viewer, 
to identify bona fide variant calls and exclude sequencing 
or alignment artifacts [21, 23, 26]. Potential pathogenic 
variants seen at frequency > 1% were also examined in the 
GnomAD database and the TSC LOVD database.
A minimal median read depth of 20x coverage for 
the coding exons of TSC1 and TSC2 was required for the 
samples reported here. The median read depth for coding 
exons of TSC1 and TSC2 was a median of 107 (range 20 
– 1120) among the 31 samples.
LOH was assessed using two allele frequencies: 
1) at the site of mutation, using Unix grep to precisely 
quantify mutant vs. wild-type reads for indel mutations; 
and 2) at all SNPs identified in the TSC1 and TSC2 genes 
that had a population allele frequency of > 0.05% in the 
GnomAD database. If either the mutant allele frequency 
for the mutation was > 55%, or the median SNP minor 
allele frequency for TSC1/TSC2 was < 40%, this was 
considered evidence of CN-LOH. LOH was assessed only 
in the tumor samples; normal brain tissue adjacent to the 
tumor, was not available.
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